Literature DB >> 7003235

Relief from malignant hypertension by treatment with captopril in a patient on maintenance hemodialysis.

H Witzgall.   

Abstract

A patient with end-stage renal disease due to malignant hypertension is described. Hypertension was resistant to hemodialysis. The orally active inhibitor of angiotensin-converting enzyme captopril (SQ 14.255; 2-D-methyl-3-mercaptopropanoyl-L-protein) dramatically lowered the elevated blood pressure both under ambulatory and dialysis conditions. No side effects were observed after 6 months' treatment. The effect of captopril could be described as a "biochemical nephrectomy".

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7003235     DOI： 10.1007/bf01476998

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  7 in total

1.  Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme.

Authors:  E D Vaughan; R M Carey; C R Ayers; M J Peach
Journal:  J Clin Endocrinol Metab       Date:  1979-05       Impact factor: 5.958

2.  Reaction constants of renin in juxtaglomerular apparatus and plasma renin activity after renal ischemia and hemorrhage.

Authors:  P Weber; E Held; E Uhlich; J O Eigler
Journal:  Kidney Int       Date:  1975-05       Impact factor: 10.612

3.  Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.

Authors:  S A Atlas; D B Case; J E Sealey; J H Laragh; D N McKinstry
Journal:  Hypertension       Date:  1979 May-Jun       Impact factor: 10.190

4.  Hypertension in end-stage renal disease.

Authors:  V Vertes; J L Cangiano; L B Berman; A Gould
Journal:  N Engl J Med       Date:  1969-05-01       Impact factor: 91.245

5.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

6.  Indomethacin (IND) inhibits an enhanced renin release following the captopril, SQ 14225, administration.

Authors:  K Abe; T Itoh; M Satoh; T Haruyama; Y Imai; T Goto; K Satoh; Y Otsuka; K Yoshinaga
Journal:  Life Sci       Date:  1980-02-18       Impact factor: 5.037

7.  Paper chromatographic systems for the separation of aldosterone, 18-hydroxycorticosterone, 18-hydroxydeoxycorticosterone, corticosterone and deoxycorticosterone.

Authors:  H Witzgall; S Hassan-Ali
Journal:  J Chromatogr       Date:  1980-09-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.